Sorcha A Collins1, Gertrude Elizabeth Hildes-Ripstein2, James Robert Thompson3, Sharon Edmunds4, Amber Miners5, Cheryl Rockman-Greenberg2, Laura Arbour1. 1. Department of Medical Genetics, University of British Columbia, Victoria, British Columbia. 2. Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba. 3. Cadham Provincial Laboratory, Winnipeg, Manitoba. 4. Department of Social and Cultural Development, Nunavut Tunngavik Inc., Iqaluit, Nunavut. 5. Department of Health, Government of Nunavut, Iqaluit, Nunavut.
Abstract
INTRODUCTION: Neonatal hypoglycemia (NH) in the first days of life can largely be prevented by recognizing those at risk and managing accordingly. The CPT1A P479L variant is prevalent in northern Indigenous populations and is a possible risk factor for hypoglycemia. We report on NH incidence in the Kivalliq region of Nunavut, where all Inuit newborns are screened for NH. METHODS: We reviewed clinical charts of 728 Inuit newborns from Kivalliq (January 1, 2010 to December 31, 2013) for blood glucose (BG) levels and infant/maternal characteristics, linking to CPT1A genotype; 616 newborns had BG data from 2 to 48 hours of life. NH was defined using Canadian Paediatric Society guidelines (≤2.0 mmol/L at 2 hours, <2.6 mmol/L at 2 to 48 hours). RESULTS: NH was documented in 21.4% overall, 24.4% of at-risk newborns and 19.5% of term newborns with no risk factors (≥37 weeks gestation, term-NRF). NH was documented in 22.0% of CPT1A P479L homozygous, 19.8% of P479L heterozygous and 4.8% of noncarrier term-NRF newborns. With multivariable logistic regression, the adjusted ORs for developing NH in term-NRF newborns was 4.97 for CPT1A P479L homozygotes (95% confidence interval [CI]:0.65-38.35, P=0.19) and 4.71 for P479L heterozygotes (95% CI:0.57-37.89, P=0.15). CONCLUSION: Term-NRF newborns had a higher NH incidence than previously reported, similar to that for at-risk newborns, possibly due to the CPT1A P479L variant. Since only Inuit newborns from Kivalliq are screened for NH, further study of long-term outcomes of NH in this population and the role of the P479L variant are warranted to determine if neonatal BG screening is indicated in all Inuit newborns.
INTRODUCTION: Neonatal hypoglycemia (NH) in the first days of life can largely be prevented by recognizing those at risk and managing accordingly. The CPT1A P479L variant is prevalent in northern Indigenous populations and is a possible risk factor for hypoglycemia. We report on NH incidence in the Kivalliq region of Nunavut, where all Inuit newborns are screened for NH. METHODS: We reviewed clinical charts of 728 Inuit newborns from Kivalliq (January 1, 2010 to December 31, 2013) for blood glucose (BG) levels and infant/maternal characteristics, linking to CPT1A genotype; 616 newborns had BG data from 2 to 48 hours of life. NH was defined using Canadian Paediatric Society guidelines (≤2.0 mmol/L at 2 hours, <2.6 mmol/L at 2 to 48 hours). RESULTS: NH was documented in 21.4% overall, 24.4% of at-risk newborns and 19.5% of term newborns with no risk factors (≥37 weeks gestation, term-NRF). NH was documented in 22.0% of CPT1A P479L homozygous, 19.8% of P479L heterozygous and 4.8% of noncarrier term-NRF newborns. With multivariable logistic regression, the adjusted ORs for developing NH in term-NRF newborns was 4.97 for CPT1A P479L homozygotes (95% confidence interval [CI]:0.65-38.35, P=0.19) and 4.71 for P479L heterozygotes (95% CI:0.57-37.89, P=0.15). CONCLUSION: Term-NRF newborns had a higher NH incidence than previously reported, similar to that for at-risk newborns, possibly due to the CPT1A P479L variant. Since only Inuit newborns from Kivalliq are screened for NH, further study of long-term outcomes of NH in this population and the role of the P479L variant are warranted to determine if neonatal BG screening is indicated in all Inuit newborns.
Authors: Charles A Stanley; Paul J Rozance; Paul S Thornton; Diva D De Leon; Deborah Harris; Morey W Haymond; Khalid Hussain; Lynne L Levitsky; Mohammad H Murad; Rebecca A Simmons; Mark A Sperling; David A Weinstein; Neil H White; Joseph I Wolfsdorf Journal: J Pediatr Date: 2015-03-25 Impact factor: 4.406
Authors: Melanie B Gillingham; Matthew Hirschfeld; Sarah Lowe; Dietrich Matern; James Shoemaker; William E Lambert; David M Koeller Journal: Mol Genet Metab Date: 2011-06-28 Impact factor: 4.797
Authors: Sorcha A Collins; Graham Sinclair; Sarah McIntosh; Fiona Bamforth; Robert Thompson; Isaac Sobol; Geraldine Osborne; Andre Corriveau; Maria Santos; Brendan Hanley; Cheryl R Greenberg; Hilary Vallance; Laura Arbour Journal: Mol Genet Metab Date: 2010-07-24 Impact factor: 4.797
Authors: Brian T Bateman; Elisabetta Patorno; Rishi J Desai; Ellen W Seely; Helen Mogun; Ayumi Maeda; Michael A Fischer; Sonia Hernandez-Diaz; Krista F Huybrechts Journal: Pediatrics Date: 2016-09 Impact factor: 7.124
Authors: Cheryl R Greenberg; Louise A Dilling; G Robert Thompson; Lorne E Seargeant; James C Haworth; Susan Phillips; Alicia Chan; Hilary D Vallance; Paula J Waters; Graham Sinclair; Yolanda Lillquist; Ronald J A Wanders; Simon E Olpin Journal: Mol Genet Metab Date: 2009-02-13 Impact factor: 4.797
Authors: Sirui Zhou; Lan Xiong; Pingxing Xie; Amirthagowri Ambalavanan; Cynthia V Bourassa; Alexandre Dionne-Laporte; Dan Spiegelman; Maude Turcotte Gauthier; Edouard Henrion; Ousmane Diallo; Patrick A Dion; Guy A Rouleau Journal: PLoS One Date: 2015-05-26 Impact factor: 3.240
Authors: Bradford D Gessner; Thalia Wood; Monique A Johnson; Carolyn Sue Richards; David M Koeller Journal: Genet Med Date: 2016-01-28 Impact factor: 8.822
Authors: Sorcha A Collins; Sharon Edmunds; Gwen Healey Akearok; J Robert Thompson; Anders C Erickson; Elske Hildes-Ripstein; Amber Miners; Martin Somerville; David M Goldfarb; Cheryl Rockman-Greenberg; Laura Arbour Journal: Front Pediatr Date: 2021-07-06 Impact factor: 3.418